

IJRP December 2022 Edition: Letter of Acceptance

Dari: IJRP December 2022 Edition: Letter of Acceptance (publish@ijrp.org)

Kepada: daniarsy05@gmail.com; dr_setia76@yahoo.co.id; medortho@gmail.com; sjahjenny@gmail.com

Tanggal: Rabu, 14 Desember 2022 05.25 WIB

Dear Author,

We are delighted to inform that your research paper has been Accepted for Publication in International Journal of Research Publications (IJRP) **December 2022** Edition.

** Please send total registration fee- **41.96 USD** (40 USD Registration fees+ 1.96 USD for PayPal transaction fees) to our PayPal account: "**editor.ijrp@gmail.com**" or click here to visit the Payment [Link](#)

Note: Since we have selected a limited number of papers for the **December 2022** , Can you do the formalities by **21 Dec 2022** If you have any query, please let us know ASAP.

Paper Title: "Correlation Analysis of The Risk Factors for Pathological Fracture Using Mirels Classification in Long Bone Metastatic Disease"

Paper Reference ID: : 10011411220224226

Reviewer Comments:

Status: Accepted

Reason: Overall is good, but there are some things that need to be revised. Authors need add a few recent references. Finally recommended for publication

REFEREE'S REPORT: SUMMARY SHEET:

EVALUATION CRITERIA	SCORE(0-10)
1. Relevance of Topic	7
2. Scholarly Quality	6
3. English Usage	6
4. Use of Theory	7
5. Novelty and Originality of the idea	8
6. Technical Content and Correctness	7
7. Critical Qualities	8
8. Clarity of Conclusions	7
Total Score	7

** Please take note, plagiarism of the final manuscript should be less than 30%

The important deadlines regarding publication are as follows:

Camera-ready paper submission: 21 Dec 2022

Copyright transfer: 21 Dec 2022

You are requested to re-submit your paper as Camera Ready Copy (CRC) in DOC/ DOCX and/or Latex file format conforming to the prescribed [IJRP Paper Template](#) on or before 21 Dec 2022. (Login to your ijrp portal to upload final/camera-ready manuscript and copyright form)

You can login with your Email Address and Password. After login, you can Upload Final Manuscript, copyright form, Donation Payment Receipt.

Your Paper ID: 10011411220224226

Login URL: <http://ijrp.org/login>

If you forget your Email Address and password, You can also Upload Final Manuscript, copyright form, Donation Payment Receipt with the below link.

<https://ijrp.org/journalfileUplaod/af53ecba7ecbe74e3f2236f7f2cd03537eaa90f4>

Your Paper ID : 10011411220224226

--

Sincerely,
Editorial Assistant
International Journal of Research Publications
<http://www.ijrp.org/>

Fw: Paper Published in Volume 114

Dari: ROSY SETIAWATI (dr_setia76@yahoo.co.id)

Kepada: msksoetomo.unair@gmail.com; drsetiarosy19@gmail.com

Tanggal: Jumat, 3 Februari 2023 13.25 WIB

[Sent from Yahoo Mail on Android](#)

----- Forwarded Message -----

From: "Editor IJRP" <ijrp.cfp@gmail.com>

To: "daniarsy05@gmail.com" <daniarsy05@gmail.com>, "dr_setia76@yahoo.co.id" <dr_setia76@yahoo.co.id>, "medortho@gmail.com" <medortho@gmail.com>, "sjahjenny@gmail.com" <sjahjenny@gmail.com>

Sent: Wed, Dec 14, 2022 at 2:03 PM

Subject: Paper Published in Volume 114

Dear Author,

Your paper has been successfully published in the volume - 114

Paper Title: Correlation Analysis of The Risk Factors for Pathological Fracture Using Mirels' Classification in Long Bone Metastatic Disease.

Paper ID: 10011411220224226

Download your certificate from here -

<https://ijrp.org/check-status>

Kindly check our web archive for more information.

--

Sincerely,

Editorial Assistant

**International Journal of Research Publications,
ISSN (2708-3578) (Online),**

www.ijrp.org

IJRP Copyright Form

Paper ID: 10011411220224226

Title of Work: Correlation Analysis of The Risk Factors for Pathological Fracture Using Mirels' Classification in Long Bone Metastatic Disease

Author(s): Dania Raisya Safira; Rosy Setiawati*; Mouli Edward; Sjahjenny Mustokoweni

TRANSFER OF COPYRIGHT AGREEMENT

Copyright to the above work (including without limitation, the right to publish the work in whole or in part in any and all forms of media, now or hereafter known) is hereby transferred to the IJRP (*for Government work, to the extent transferable -see Part B below) effective as of the date of this agreement, on the understanding that the work has been accepted for publication by IJRP.

However, each of the Employer/Author(s) retains the following rights:

1. All other proprietary rights to the work such as patent
2. The right to reuse any portion of the work, without fee, in future works of the Employer/Author's own,** including books, lectures and presentations in all media, provided that the IJRP citation and notice of the Copyright are included (See Part A below).
3. The right to revise the work. Please mail the Editor at editor@IJRP.org to upload any revisions to existing work.
4. The right to post author-prepared versions of the work covered by IJRP copyright in a personal collection on their own Home Page and on a publicly accessible server of their employer. Such posting is limited to noncommercial access and personal use by others, and must include this notice both embedded within the full text file and in the accompanying citation display as well, i.e.:

"© IJRP, (YEAR). This is the author's version of the work. It is posted here by permission of IJRP for your personal use. Not for redistribution. The definitive version was published in PUBLICATION, {VOL#, NUM#, (DATE)}"
5. (Article DOIs are on their citation pages in the IJRP Digital Library.)
6. The right of an employer who originally owned copyright to distribute definitive copies of its author-employees work within its organization. Posting these works for world access requires explicit permission from IJRP.

A. ASSENT TO ASSIGNMENT

This Form must be signed by the lead author or, in the case of a "work made for hire," by the employer and must be received by IJRP before processing of the manuscript for publication can be completed.

Authors should understand that consistent with IJRP's policy of encouraging dissemination of information, each work published by IJRP appears with the IJRP copyright and the following notice:

"Intellectual properties and scientific inventions published with IJRP are protected under International and Federal Copyright Laws and Treaties. Permission to make digital or hard copies of part or all of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than IJRP must be honored. Abstracting with credit is permitted. To copy otherwise, to republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee."

However, it is at the discretion of IJRP if the copyright notice should be included in the published manuscript.

I hereby warrant that I am the sole owner (or authorized agent of the copyright owner(s)), with the exception of third party material detailed in Part C below. Permission has been obtained for third party material included in this paper.

Signature



Print Name

Date 14 - 12 - 2022

B. *DECLARATION FOR GOVERNMENT WORK (See IJRP Copyright Procedures below)

This section is applicable if the published material belongs to any government organization.

A modified copyright statement regarding government use will appear on the published work.

This certifies that the above author(s) wrote the paper (a) as part of work as government employee(s) or, (b) as other government work.

Signature _____

Agency _____

Title, if not Author _____

Date _____

C. Third-Party Material

This copyright transfer applies only to the work as a whole, not to any embedded objects owned by third parties. An author who embeds an object, such as an art image that is copyrighted by a third party, must obtain that party's permission to include the object, with the understanding that the entire work may be distributed as a unit in any medium. The requirement to obtain third-party permission does not apply if the author embeds only a link to the copyright holder's definitive version of the object.

Third-party permission must be clearly stated near the object(s) or in the text narrative. Indicate below any third-party material included in this submission. Please be specific, i.e, type of material: figure, table, photo, music, video or other image, and note whether permission is approved (Y/N) and forwarded to IJRP with your submission. (*Use a separate sheet if additional space is required.*)

	IJRP reference	Third-party reference	Approved (Y/N)	Date
1.	_____	_____	_____	_____
2.	_____	_____	_____	_____
3.	_____	_____	_____	_____

D. Mailing Address:

Please return this form by email after signing to:

Editor
 IJRP Journal,
 editor@IJRP.org
 www.IJRP.org

E. Collaboration

International Journal of Research Publications (IJRP) supports highly-automated electronic archive and distribution server for research articles. Covered areas include physics, mathematics, computer science, nonlinear sciences, quantitative biology and statistics, and many other fields.

The IJRP copyright arrangements allow several University Library non-exclusive and irrevocable license to distribute or certify that the work is available under IJRP license that conveys these rights. IJRP authority has the right to take any actions, if necessary. IJRP authority will not take any responsible for any unethical practices (if any) done by authors.

Fw: IJRP Paper Submission: December 2022 Edition

Dari: ROSY SETIAWATI (dr_setia76@yahoo.co.id)

Kepada: drsetiarosy19@gmail.com

Tanggal: Jumat, 3 Februari 2023 13.21 WIB

[Sent from Yahoo Mail on Android](#)

----- Forwarded Message -----

From: "IJRP Paper Submission: December 2022 Edition" <publish@ijrp.org>

To: "dr_setia76@yahoo.co.id" <dr_setia76@yahoo.co.id>

Sent: Fri, Dec 9, 2022 at 6:04 PM

Subject: IJRP Paper Submission: December 2022 Edition

Dear **Rosy Setiawati**,

Thank you for the research paper submission towards IJRP **December 2022** Edition. The manuscript will undergo peer and formal review rounds within IJRP reviewer's network. Each submitted article is assigned a mandatory fifteen days of review period and the results will be notified accordingly.

Save below information for further communication.





Paper Title: "Correlation Analysis of The Risk Factors for Pathological Fracture Using Mirels'™ Classification in Long Bone Metastatic Disease"

Paper Reference ID: : 10011411220224226

Author List

#	Author Name	Author Email	Corresponding Author
1	Dania Raisya Safira	daniarsy05@gmail.com	No
2	Rosy Setiawati	dr_setia76@yahoo.co.id	Yes
3	Mouli Edward	medortho@gmail.com	No
4	Sjahjenny Mustokowen	sjahjenny@gmail.com	No

--
Sincerely,
Editorial Assistant
<https://ijrp.org/>

	Signature	Name	Authors	Date
1.	 _____	Dania Raisya Safira _____	First _____	14 Desember 2022 _____
2.	 _____	Rosy Setiawati _____	Corresponding _____	14 December 2022 _____
3.	 _____	Mouli Edward _____	Second _____	14 December 2022 _____
4.	 _____	Sjahjenny Mustokoweni _____	Third _____	14 December 2022 _____

Fw: Registration for IJRP Volume 114

Dari: ROSY SETIAWATI (dr_setia76@yahoo.co.id)

Kepada: drsetiarosy19@gmail.com; msksoetomo.unair@gmail.com

Tanggal: Jumat, 3 Februari 2023 13.24 WIB

[Sent from Yahoo Mail on Android](#)

----- Forwarded Message -----

From: "Editor IJRP" <editor.ijrp@gmail.com>

To:

Sent: Wed, Dec 14, 2022 at 5:23 AM

Subject: Registration for IJRP Volume 114

Dear Author,

Congratulations and Greetings,

We would like to inform you -your submission to IJRP (ISSN: 2708-3578) got accepted in IJRP *volume 114*.

This is a general email for your paper registration.

Please complete the registration process asap as the deadline is: ***17th December 2022***.

Registration fee: 41.96 USD (40 USD for registration fees + 1.96 USD for PayPal transaction fees).

Please send the registration fees to our PayPal account: "editor.ijrp@gmail.com" or click the given Payment ([click here](#)).

Following the IJRP template and plagiarism less than 30%, is mandatory for final publication. ([Download template and copyright](#))

Our Indexing Partner: **Crossref**

IJRP DOI: <https://doi.org/10.47119/27083578>

If we don't hear anything from you within the deadline, the paper will be automatically removed from our accepted list as well as from the journal. If you need more days to complete registration, please let us know.

[Check reviewer comments in our automatic acceptance email, which is already sent to you.]

--

Sincerely,

Editorial Assistant,

International Journal of Research Publications (IJRP).

ISSN: (2708-3578).

www.ijrp.org



IJRP.ORG

International Journal of Research Publications

ISSN: 2708-3578 (Online)

Certificate of Publication

THIS IS TO CERTIFY THAT

Dania Raisya Safira, Rosy Setiawati, Mouli Edward, Sjahjenny Mustokoweni

Volume 114 , Issue 1, December 2022

PUBLISHED A PAPER ENTITLED


Correlation Analysis of The Risk Factors for Pathological Fracture Using Mirels' Classification in Long Bone Metastatic Disease

10011411220224226

REFERENCE NO:

Editor in Chief

www.ijrp.org



Correlation Analysis of The Risk Factors for Pathological Fracture Using Mirels' Classification in Long Bone Metastatic Disease

Dania Raisya Safira^a, Rosy Setiawati^b, Mouli Edward^c, Sjahjenny Mustokoweni^d

^aFaculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; daniarsy05@gmail.com

^bRadiology Department, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia;
dr_setia76@yahoo.co.id

^cOrthopaedic and Traumatology Department, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia;
medortho@gmail.com

^dPathology Anatomy Department, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia;
sjahjenny@gmail.com

Abstract

Background: Pathological fracture is one of the consequences from MBD, which can worsen the prognosis and can deplete the quality of patients' lives. Looking at those effects, predicting the pathological fracture in MBD patients needs to be done. Objective: Determine the correlation of risk factors for pathological fractures in long bone metastatic disease and determine the accuracy of the Mirels' scoring system. Method: This was a retrospective research based on the medical record data and x-ray photos of patients with long bone metastases at Dr. Soetomo General Academic Hospital in 2019-2021. We determined the correlation of risk factors by using the likelihood-ratio test. Result: Of the total of 39 long bone metastases cases, there were 28 cases (71.79%) followed by pathological fracture, and 11 of them (28.21%) were not. From the calculation of Mirels' score, 36 cases had scores of ≥ 9 (impending), and 3 of them had scores of 8 (borderline). Most metastases were located in the lower extremities (48.7%), sized $>2/3$ cortex (48.7%), lytic type (79.5%), and with functional pain (82.1%). Conclusion: There was a correlation between the location of upper extremity lesions sized $> 2/3$ cortex, lytic type, and functional pain with the incidence of fracture ($p < 0,05$) and the percentage of Mirel's scoring system accuracy in predicting the incidence of pathological fractures was 66.67%.

Keywords: Long bone metastases; pathological fracture; Mirels' scoring; MBD

1. Introduction

Metastatic bone disease is a type of cancer from primary tumor cells from an area that spread to the bone⁽¹⁾. Bone is the third most common site of metastases after the lungs and liver. Breast and prostate cancer are responsible for most bone metastases incidence. Bone metastases are one of the leading causes of morbidity⁽²⁾. It usually causes severe pain, impaired mobility, and a high chance of bone complications, such as pathologic fracture incidence⁽³⁾. Pathologic fractures are not caused by excessive pressure but by weakened bone due to a tumor⁽⁴⁾. The incidence of bone metastases followed by pathologic fractures can cause the patient to have a worsened quality of life, increased anxiety, and increased depression⁽⁵⁾.

The potential effects make predicting the risk of pathologic fractures in patients with bone metastases important⁽⁶⁾. One of the methods that can be used to predict the risk is Mirel's scoring system or Mirel's classification system. The system can predict the risk of pathologic fracture based on four variables that are

believed to contribute to the risk of pathologic fracture: site, size, type, and pain level. These variables will then be assessed with progressive scores ranging from 1 to 3. The scores then accumulated with a maximum value of 12⁽⁷⁾.

This study aims to analyze the correlation between risk factors on long bone metastases and pathologic fracture incidence using Mirel's classification and to determine the accuracy of Mirel's scoring system. The analysis results can be a reference for the community and health professionals to prevent fractures and reduce morbidity.

2. Methods

This paper was analytic retrospective research of metastatic bone disease patients at the Radiology department and Orthopaedic and Traumatology Department, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. The data was based on the medical record and x-ray photos of patients with long bone metastases at Dr. Soetomo General Academic Hospital from January 2019 until October 2021. Patients diagnosed with long bone metastases, with or without pathological fracture, were included as the research's subjects. This study was approved by the Research Ethics Committee of Dr. Soetomo General Academic Hospital with number 0656/LOE/101.4.2/2021.

Using SPSS software, the Chi-Square test, all samples that met the inclusion criteria were analyzed to determine the correlation of risk factors for pathological fractures in long bone metastatic disease and to determine the accuracy of Mirel's scoring system.

3. Results

Based on the data, 39 patients with long bone metastases, both with and without pathological fractures, fit the inclusion criteria.

Table 1. Distribution of gender and age of patients with long bone metastases

Characteristics	N	%
Gender		
Male	12	30,77%
Female	27	69,23%
Age		
Mean	51,16	-
Youngest	5	-
Oldest	68	-
<25	1	2,56%
25-50	15	38,46%
>50	23	58,97%

The data showed that there are more female patients than male patients. There were 27 female patients (69.23%) and 12 male patients (30.77%). Based on the age group, the highest proportion was found in > 50 years old patients, with 23 cases (58.97%). The oldest patient was 68 years old, with long bone metastases from cervical tumors, and the youngest was 5 years old, with long bone metastases from neuroblastoma tumors.

Table 2. Distribution of primary tumors in patients with long bone metastases

Primary tumor	N	%
---------------	---	---

Breast	9	23,08%
Lung	8	20,51%
Thyroid	8	20,51%
Soft tissue	4	10,26%
Renal	2	5,13%
Pancreas	2	5,13%
Adrenal	1	2,56%
Esophagus	1	2,56%
Rectum	1	2,56%
Cervix	1	2,56%
Multiple myeloma	1	2,56%
Unknown origin	1	2,56%

The most common cause of long bone metastases in patients at Dr. Soetomo General Academic Hospital from 2019-2021 was breast tumors, followed by lung and thyroid tumors.

Table 3. Distribution of metastatic sites in long bones

Location	N	%
Femur	17	43,59%
Humerus	11	28,21%
Tibia	8	20,51%
Fibula	3	7,69%

The most site of metastasis was on the femur (43.59%), followed by the humerus bone (28.21%), tibia bone (20.51%), and fibula bone (7.69%).

Table 4. Distribution of histopathological examination results

Histopathology Examination	N	%
Adenocarcinoma	11	28,21%
Lung	5	12,82%
Breast	1	2,56%
Rectum	1	2,56%
Esophagus	1	2,56%
Multiple myeloma	1	2,56%
Renal clear cell	1	2,56%
Unknown origin	1	2,56%
Ductal	8	20,51%
Follicular thyroid	6	15,38%
Neuroendocrine	5	12,82%
Squamous cell carcinoma	5	12,82%
Lung	4	10,26%
Breast	1	2,56%
Papillary thyroid	2	5,13%
Cortical adrenal	1	2,56%
Nephroblastoma	1	2,56%

Based on the histopathological results, the highest percentage was adenocarcinoma (28.21%), with lung adenocarcinoma having the highest proportion, followed by ductal (20.51%), and follicular thyroid (15.38%).

Table 5. Characteristics of metastatic lesions in long bone metastatic patients

Lesion Characteristics	N	%
Location according to Mirels' scoring system		
Upper limb	11	28,21%
Lower limb	19	48,72%
Trochanteric region	9	23,08%
Size		
<1/3 of cortex	9	23,08%
1/3-2/3 of cortex	11	28,21%
>2/3 of cortex	19	48,72%
Type		
Blastic	0	0,00%
Mixed	8	20,51%
Lytic	31	79,49%
Pathological fracture		
With	28	71,79%
Without	11	28,21%

The highest prevalence of lesions characteristic were lesions located in the lower limb with 19 cases (48.72%), followed by lesions sized more than 2/3 of the cortex with 19 cases (48.72%), lytic lesions with 31 cases (79.49%), and lesions that followed by pathological fractures with 28 cases (71.79%).

Table 6. Pain level in patients with long bone metastases

Pain Scale	N	%
VAS score		
0,5-4,4	0	0,00%
4,5-7,4	7	17,95%
7,5-10	32	82,05%
Mean	8,7	-
Pain scale according to Mirels' scoring system		
Mild	0	0,00%
Moderate	7	17,95%
Functional	32	82,05%

Based on the data, the majority (82.05%) of patients had VAS scores of 7.5-10 and were in the functional pain category. The average VAS score in patients with long bone metastases at Dr. Soetomo General Academic Hospital in 2019-2021 was 8.71.

Table 7. The total score of patients with long bone metastases based on the Mirels scoring system

Total score	N	%
≤ 7 (<i>not impending</i>)	0	0,00%
8 (<i>borderline</i>)	3	7,69%
≥ 9 (<i>impending</i>)	36	92,31%

A total of 36 samples had a score of ≥ 9 and were in the impending fracture category (92.31%), and 3 samples had a score of 8 and were in the borderline category.

The Chi-Square statistical test using SPSS software found a correlation between the location of upper extremity with the incidence of pathological fractures ($p = 0.003$). The statistical tests also found a correlation between lesions in the upper extremities sized more than 2/3 of the cortex with the incidence of pathological fractures ($p = 0.014$). For the type of lesion, there was a correlation between the lytic type of upper extremity lesions with the incidence of pathological fractures ($p = 0.003$). For the pain level, there was a correlation between lesions in the upper extremities with functional pain levels and the incidence of pathological fractures ($p = 0.005$), and also there was a correlation between lesions in the lower extremities with functional pain levels and the incidence of pathological fractures ($p = 0.044$).

Table 8. Calculation of the accuracy of Mirels scoring system

		Score Prediction Result			Total	% of prediction accuracy
		Not impending	Borderline	Impending		
Observation result	With no pathological fracture	0	1	10	11	
	With pathological fracture	0	2	26	28	
	Total	0	3	36	39	66,67%

Of 39 patients, 11 did not experience pathological fractures, and 28 had pathological fractures. Of the 11 patients who did not have pathological fractures, according to Mirels' classification, 1 was in the borderline category, and 10 were in the impending fracture category. Of the 28 patients with pathological fractures, according to the Mirels classification, 2 were in the borderline category, and 26 were in the impending fracture category. The percentage of total accuracy calculated was 66.67%.

4. Discussion

In this study, the data showed that there are more female patients than male patients. There were 27 female patients (69.23%) and 12 male patients (30.77%). According to the research by Yang et al. (2016), of 3223 patients with bone metastases, 1708 were female (53%), and 1515 were male (47%)⁽⁸⁾. A systematic review by Farach-Carson et al. (2017) stated that sex hormone such as estrogen influence the pathogenesis of primary tumor growth and bone metastases⁽⁹⁾. The data in this study found that the highest number of primary tumors causing long bone metastases were breast tumors, which were only found in female patients. Based on the age group following the study by Yang et al., the highest proportion of age groups was patients aged 50-70 years old⁽⁸⁾.

The distribution of the primary tumors revealed that the most common tumors that cause long bone metastases were breast and lung tumors. Similar to research from the University of South Florida by Henderson Jackson et al. (2016), the highest prevalence of primary tumors that cause long bone metastases was breast tumors, with 20 patients (24%), followed by lung tumors (19%)⁽¹⁰⁾. Unlike the research by Yang et al. (2016), the highest prevalence of primary tumors was lung tumors (36.5%), followed by breast tumors (30.9%) and prostate tumors (8.5%)⁽⁸⁾. Based on the research by W. Z. Chen et al. (2017), the site of long bone metastases from breast tumors was mainly in the femur, with 81 cases (24.8%)⁽¹¹⁾. Bone metastases from breast tumors were mainly osteolytic type and pathological fractures were common in patients with metastases from breast tumors^(12,13). A study by Zhou et al. (2017) found that the most common site for long bone metastases from lung tumors was the femur, with 71 of 108 cases metastasizing to the long bones⁽¹⁴⁾. Most long bone metastases from lung tumors showed osteolytic lesions on radiological images⁽¹⁵⁾. It indicated that pathological fractures were skeletal-related events that often occur in patients with primary lung

tumors⁽¹⁶⁾. The data in this study found that the most common metastases occurred in the femur. The result was similar with the study by Shimada et al. (2014), in which 50 cases of long bone metastases, 56% of cases occurred in the femur, 32% in the humerus, and 12% in the tibia⁽¹⁷⁾. Based on the histopathological examination in this study, most of the tumors were the adenocarcinoma type. Based on the research by Hui et al., the histopathological examination with the highest prevalence was adenocarcinoma types (52%), followed by thyroid carcinoma types which were divided into follicular and papillary carcinomas⁽¹⁸⁾. In this study, the second highest prevalence was the ductal type. It happened because breast tumors caused most long bone metastases cases. The American Cancer Society (2021) stated that histologically, more than 75% of breast tumor cases were of the ductal type⁽¹⁹⁾.

Bone metastases are the most common cause of pain in patients with malignant diseases⁽²⁰⁾. Thus, Mirels included the pain level in the scoring system⁽⁷⁾. The average VAS score in patients with long bone metastases at Dr. Soetomo General Academic Hospital in 2019-2021 was 8.71 (functional pain). This study's results are similar to the study by Hiba et al. (2022), which stated that the average VAS score of 117 patients was 8.7 ± 1.5 ⁽²⁰⁾. Clinical analysis showed that osteolytic lesions were closely related to the occurrence of pain. Osteoclast activity is under the influence of tumor necrosis factor-alpha (TNF alpha) and other cytokines secreted by cancer cells. Then the osteoclasts secrete protons and acidic enzymes that break down the bone. The acidic environment activates nociceptors which give rise to the perception of pain⁽²¹⁾.

After calculating using the Mirels' scoring system, 36 samples (92.31%) scored ≥ 9 and were classified in the impending fracture category. It indicated that most patients with long bone metastases at Dr. Soetomo General Academic Hospital in 2019-2021 were likely to experience a pathological fracture. It happened because Dr. Soetomo General Academic Hospital is a type A hospital with the highest referral in Eastern Indonesia⁽²²⁾. It may be why most of the patients with long bone metastases were in a complex or severe condition, marked by the accumulated Mirels score of more than 9.

Statistically, there was a correlation between the site of lesions in the upper extremities with the incidence of pathological fractures ($p = 0.003$) and there was a correlation between lesions in the upper extremities sized more than $2/3$ of the cortex with the incidence of pathological fractures ($p = 0.014$). It happened because more than half of the samples (72.7%) in the upper extremities had lesions that are more than $2/3$ of the cortex, while only 42.1% of the samples in the lower extremities and only 33.3% of the samples in the trochanteric area were larger than $2/3$ of the cortex. Hoban et al. (2022) stated that the lesion size had a significant relationship with the incidence of pathological fractures ($p < 0.001$)⁽²³⁾. For the type of lesion variable, it was found that there was a correlation between the lytic type lesions in upper extremities with the incidence of pathological fractures ($p = 0.003$). In this study, all cases (100%) of metastases in the long bones of the upper extremities were having the lytic type. According to Mirel's original literature, cases of long bone metastases with lytic lesions were significantly associated with the incidence of pathological fractures⁽²⁴⁾. Lytic lesions can occur due to tumors' osteoclast activation, which results in increased RANKL ligand activity. Lytic lesions often cause pathological fractures due to biomechanical changes and cause the bones to be weak and fractures⁽²⁵⁾. For the pain level variable, there was a correlation between lesions in the upper extremities with functional pain levels and the incidence of pathological fractures ($p = 0.005$), and there was a correlation between lesions in the lower extremities with functional pain levels and the incidence of pathological fractures ($p = 0.044$). In the study by Evans et al. (2008), the risk factor for pain level correlated significantly with the incidence of pathological fracture ($p < 0.0001$)⁽²⁶⁾. There was a close relationship between the level of functional pain and the lesion size, where 90% (19 out of 21) of patients who experienced functional pain had lesions sized more than $2/3$ of the cortex⁽²⁴⁾. In this study, most lesions in the upper and lower extremities were sized more than $2/3$ of the cortex, whereas, in the trochanteric area, only one-third of cases with a size of more than $2/3$ of the cortex.

This study found that the percentage of total accuracy of the scoring system from Mirels was 66.67%. Based on Howard, Cool, and Cribb (2019), the specificity of the scoring system from Mirels is around 35%⁽²⁷⁾. Other studies said that the specificity of the Mirels scoring is 50%, and the sensitivity is 71%⁽²⁸⁾. In

this study, things that could be the cause were because Dr. Soetomo General Academic Hospital is a type A hospital and is the highest referral hospital in Eastern Indonesia. So patients who came to Dr. Soetomo Hospital tend to be in a severe and complex condition⁽²²⁾. In addition, the level of health-seeking behavior in Indonesia is still relatively low, and Indonesians prefer non-formal health providers (e.g., traditional medicine, acupuncture, massage, and hypnotherapy)⁽²⁹⁾. It probably why in this study, many patients with long bone metastases came with pathological fractures.

This research has several limitations. First, the sample distribution was not equal in each variable and relatively limited. Second, there were samples with large lesion sizes that involved the lower extremities and trochanteric areas, making it difficult to deduce the site of the lesion. Based on Howard, Cool, and Cribb (2019), the boundary between the lower extremities and the trochanteric was not written in the original literature, so it is quite difficult to decide whether the lesion was in the lower extremities or trochanteric⁽²⁷⁾. Thus, a similar study with a larger number of samples with a more equal sample distribution is needed.

Currently, the latest techniques for predicting pathological fractures are CT-based structural rigidity analysis (CTRA) and finite element analysis (FEA). The CTRA and FEA techniques have a much higher specificity and sensitivity than the Mirels scoring. Respectively, the specificity and sensitivity of CTRA are 60-90% and 100%. Respectively, the specificity and sensitivity of FEA are 63-86% and 80-100%. However, these two techniques have yet to be widely used because they need sophisticated technology and technical expertise, take more time, and are expensive⁽³⁰⁾.

Until this day, Mirels' scoring system is still widely used to help predict the incidence of pathological fractures since the calculation method is simple. Regardless, it needs to be combined with other assessments and not solely just the Mirels scoring to avoid unnecessary prophylactic surgery⁽³¹⁾.

5. Conclusion

There was a correlation between the location of upper extremity lesions sized $> 2/3$ cortex, lytic type, and functional pain with the incidence of fracture. There was also a correlation between lesions in the lower extremities with functional pain with the incidence of pathological fractures ($p < 0.05$). The accuracy percentage of pathological fracture prediction on the Mirels scoring system was 66.67%. The Mirels scoring system is relatively easy and a good predictor in assisting the practice of pathological fracture management in long bone metastases. However, it needs to be combined with other assessments and not solely just the Mirels scoring to avoid unnecessary prophylactic surgery.

References

1. D'Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. Vol. 15, Journal of Bone Oncology. Elsevier GmbH; 2019.
2. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: An overview. *Oncol Rev.* 2017;11(1).
3. Cecchini MG, Wetterwald A, van der Pluijm G, Thalmann GN. Molecular and biological mechanisms of bone metastasis. *EAU Update Series.* 2005;3(4):214–26.
4. Ömeroğlu H. Basic principles of fracture treatment in children. *Eklemler Hastalıkları ve Cerrahisi.* 2018;29(1):52–7.
5. van der Vliet QMJ, Paulino Pereira NR, Janssen SJ, Hornicek FJ, Ferrone ML, Bramer JAM, et al. What Factors are Associated With Quality Of Life, Pain Interference, Anxiety, and Depression in Patients With Metastatic Bone Disease? *Clin Orthop Relat Res.* 2017 Feb 1;475(2):498–507.

6. Tanck E, van Aken JB, van der Linden YM, Schreuder HWB, Binkowski M, Huizenga H, et al. Pathological fracture prediction in patients with metastatic lesions can be improved with quantitative computed tomography based computer models. *Bone*. 2009 Oct;45(4):777–83.
7. Jawad MU, Scully SP. In brief: Classifications in brief: Mirels' classification: Metastatic disease in long bones and impending pathologic fracture. Vol. 468, *Clinical Orthopaedics and Related Research*. Springer New York LLC; 2010. p. 2825–7.
8. Yang Y, Ma Y, Sheng J, Huang Y, Zhao Y, Fang W, et al. A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China. *Chinese Journal of Cancer* 2016 35:1 [Internet]. 2016 Apr 25 [cited 2022 Sep 5];35(1):1–6. Available from: <https://cancercommun.biomedcentral.com/articles/10.1186/s40880-016-0102-6>
9. Farach-Carson MC, Li SH, Nalty T, Satcher RL. Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow? *Front Oncol* [Internet]. 2017 Aug 7 [cited 2022 Sep 5];7(AUG):163. Available from: [/pmc/articles/PMC5545941/](https://pubmed.ncbi.nlm.nih.gov/31455459/)
10. Henderson-Jackson EB, Khalil FK. Pathology of Metastatic Tumors to Bone: Effects of Decalcification as Experienced at a Single Cancer Center. *Oncology and Cancer Case Reports* [Internet]. 2016 [cited 2022 Sep 5]; Available from: <https://www.iomcworld.org/open-access/pathology-of-metastatic-tumors-to-bone-effects-of-decalcification-asexperienced-at-a-single-cancer-center-occurs-1000112.pdf>
11. Chen WZ, Shen JF, Zhou Y, Chen XY, Liu JM, Liu ZL. Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer. *Scientific Reports* 2017 7:1 [Internet]. 2017 Sep 12 [cited 2022 Sep 5];7(1):1–7. Available from: <https://www.nature.com/articles/s41598-017-11700-4>
12. Aielli F, Ponzetti M, Rucci N. Bone Metastasis Pain, from the Bench to the Bedside. *Int J Mol Sci* [Internet]. 2019 Jan 2 [cited 2022 Sep 5];20(2). Available from: [/pmc/articles/PMC6359191/](https://pubmed.ncbi.nlm.nih.gov/31455459/)
13. Filippiadis D, Mavrogenis AF, Mazioti A, Palialexis K, Megaloikonomos PD, Papagelopoulos PJ, et al. Metastatic bone disease from breast cancer: a review of minimally invasive techniques for diagnosis and treatment. *Eur J Orthop Surg Traumatol* [Internet]. 2017 Aug 1 [cited 2022 Sep 5];27(6):729–36. Available from: <https://pubmed.ncbi.nlm.nih.gov/28597402/>
14. Zhou Y, Yu QF, Peng AF, Tong WL, Liu JM, Liu ZL. The risk factors of bone metastases in patients with lung cancer. *Sci Rep* [Internet]. 2017 Dec 1 [cited 2022 Sep 5];7(1). Available from: [/pmc/articles/PMC5567132/](https://pubmed.ncbi.nlm.nih.gov/31455459/)
15. Confavreux CB, Pialat JB, Bellière A, Brevet M, Decroisette C, Tescau A, et al. Bone metastases from lung cancer: a paradigm for multidisciplinary onco-rheumatology management. 2018;
16. Oliveira MB dos R, Marques B de C, Matos RA, Fontenelle CR da C, Mello FC de Q, Paschoal MEM. PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL. *Acta Ortop Bras* [Internet]. 2018 Nov 1 [cited 2022 Sep 5];26(6):388. Available from: [/pmc/articles/PMC6362688/](https://pubmed.ncbi.nlm.nih.gov/31455459/)
17. Shimada H, Setoguchi T, Yokouchi M, Sasaki H, Ishidou Y, Kawamura I, et al. Metastatic bone tumors: Analysis of factors affecting prognosis and efficacy of CT and 18F-FDG PET-CT in identifying primary lesions. *Mol Clin Oncol*. 2014 Sep;2(5):875–81.
18. Hui M, Balu B, Uppin SG, Uppin MS, Chandrasekhar P, Rao KN, et al. Bone metastases: A compilation of 365 histologically verified cases spanning over two decades from a single center. *Indian J Pathol Microbiol* [Internet]. 2021 Oct 1 [cited 2022 Sep 5];64(4):717–24. Available from:

- <https://pubmed.ncbi.nlm.nih.gov/34673591/>
19. American Cancer Society. Breast Cancer Occurrence 3 Breast Cancer Risk Factors 12 What Is the American Cancer Society Doing about Breast Cancer? 26 Sources of Statistics 30 References 32. 2021;
 20. Hiba BA, Dorra K, Meriem R, Chayma B, Sonia K, Hanen E, et al. AB1361 PAIN MANAGEMENT IN METASTATIC BONE DISEASE. *Ann Rheum Dis* [Internet]. 2022 Jun 1 [cited 2022 Sep 5];81(Suppl 1):1786–1786. Available from: https://ard.bmj.com/content/81/Suppl_1/1786.2
 21. Ahmad I, Ahmed MM, Ahsraf MF, Naeem A, Tasleem A, Ahmed M, et al. Pain Management in Metastatic Bone Disease: A Literature Review. *Cureus* [Internet]. 2018 Sep 11 [cited 2022 Sep 5];10(9). Available from: </pmc/articles/PMC6235631/>
 22. RSUD Dr. Soetomo Surabaya. Buku Profil dan Panduan Informasi Rumah Sakit Pendidikan RSUD Dr. Soetomo [Internet]. 2017 [cited 2022 Sep 5]. Available from: <https://rsudsoetomo.jatimprov.go.id/wp-content/uploads/2021/02/Buku-Profil-dan-Panduan-Informasi-2019.pdf>
 23. Hoban KA, Downie S, Adamson DJA, MacLean JG, Cool P, Jariwala AC. Mirels' score for upper limb metastatic lesions: do we need a different cutoff for recommending prophylactic fixation? *JSES Int* [Internet]. 2022 Jul [cited 2022 Sep 5];6(4):675. Available from: </pmc/articles/PMC9264023/>
 24. Mirels H. Metastatic disease in long bones: A proposed scoring system for diagnosing impending pathologic fractures. 1989. *Clin Orthop Relat Res*. 2003;415(Suppl).
 25. Carrer A, Schairer WW, Chou D, Pekmezci M, Deviren V, Berven SH. Pathologic Fractures. Minimally Invasive Spine Surgery: Surgical Techniques and Disease Management [Internet]. 2022 May 29 [cited 2022 Sep 5];531–47. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559077/>
 26. Evans AR, Bottros J, Grant W, Chen BY, Damron TA. Mirels' Rating for Humerus Lesions is Both Reproducible and Valid. *Clin Orthop Relat Res* [Internet]. 2008 [cited 2022 Sep 5];466(6):1279. Available from: </pmc/articles/PMC2384025/>
 27. Howard EL, Cool P, Cribb GL. Prediction of pathological fracture in patients with metastatic disease of the lower limb. *Scientific Reports* 2019 9:1 [Internet]. 2019 Oct 1 [cited 2022 Sep 5];9(1):1–6. Available from: <https://www.nature.com/articles/s41598-019-50636-9>
 28. Nazarian A, Entezari V, Zurakowski D, Calderon N, Hipp JA, Villa-Camacho JC, et al. Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-based Rigidity Analysis. *Clin Cancer Res* [Internet]. 2015 Jun 6 [cited 2022 Sep 5];21(11):2514. Available from: </pmc/articles/PMC4452435/>
 29. Widayanti AW, Green JA, Heydon S, Norris P. Health-Seeking Behavior of People in Indonesia: A Narrative Review. *J Epidemiol Glob Health* [Internet]. 2020 Mar 1 [cited 2022 Nov 23];10(1):6. Available from: </pmc/articles/PMC7310809/>
 30. Kaupp SM, Mann KA, Miller MA, Damron TA. Predicting Fracture Risk in Patients with Metastatic Bone Disease of the Femur: A Pictorial Review Using Three Different Techniques. *Adv Orthop*. 2021;2021.
 31. Benca E, Patsch JM, Mayr W, Pahr DH, Windhager R. The insufficiencies of risk analysis of impending pathological fractures in patients with femoral metastases: A literature review. *Bone Rep*. 2016 Dec 1;5:51–6.